Max E. Hennig

Hennig Arzneimittel GmbH & Co. KG is a mid-sized German pharmaceutical company that has been in operation for over 120 years. The private company is based in Flörsheim am Main, Germany. The company specializes in the treatment of vertigo and vestibular disorder and is the German market leader in this area with its original drug, Arlevert®. Hennig Arzneimittel fosters research and scientific exchange among investigators in this field of study by hosting the biannual Hennig-Vertigo-Symposium, Europe's largest event in this therapeutic area. The company promotes better vertigo diagnosis and therapy by supporting continued education for practitioners, ENT-physicians, and neurologists. Hennig Arzneimittel has more than 300 highly qualified employees, state-of-the-art technologies, and its own on-site production facilities, ensuring the highest quality. The company was founded in 1898 by Max E. Hennig, and the CEOs are Kai Schleenhain and Holger Schleenhain.